Watch ATRA. Know when insiders buy.
One email the day a filing lands. Free.
Work order
80
PASS · insiders 79, shorts 81
Insiders, 90 days
+$959K
net buying · 1 buy, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $98MP/E —DIV YIELD —FCF YIELD —REV TTM $6.2M −96.7%NET INCOME −$16.7M −388.0%NET CASH —52W 4.18 – 18.09SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $630K | −96.4% | — | −$4.7M | −$4.8M | −302.5% | -0.32 | −$3.3M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | $516K | −99.5% | — | −$3.4M | −$4.1M | −110.9% | -0.29 | −$3.1M | — | — | Aug 12 |
| Q4 2025 · Dec 31derived | $1.6M | −95.1% | — | −$2.6M | −$3.4M | — | -0.36 | −$5.7M | $0 | −$5.7M | Mar 16 |
| Q3 2025 · Sep 30 | $3.5M | −91.4% | — | −$3.6M | −$4.3M | — | -0.32 | −$9.8M | $0 | −$9.8M | Nov 12 |
| Q2 2025 · Jun 30 | $17.6M | −38.6% | — | $3.2M | $2.4M | — | 0.19 | −$7.3M | $0 | −$7.3M | Aug 12 |
| Q1 2025 · Mar 31 | $98.1M | +258.8% | — | $38.8M | $38M | — | 3.50 | −$28.1M | $0 | −$28.1M | Aug 12 |
| Q4 2024 · Dec 31derived | $32.8M | — | — | −$12.2M | −$12.7M | — | -0.07 | −$24.5M | $90K | −$24.6M | Mar 16 |
| Q3 2024 · Sep 30 | $40.2M | — | — | −$21.8M | −$21.9M | — | -2.93 | −$4M | $0 | −$4M | Nov 12 |
| Q2 2024 · Jun 30 | $28.6M | — | — | −$18.2M | −$19M | — | -3.10 | −$10.6M | $29K | −$10.7M | Nov 12 |
| Q1 2024 · Mar 31 | $27.4M | — | — | −$31.2M | −$31.8M | — | -5.65 | −$29.6M | $127K | −$29.7M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$60M | −$60.5M | — | -13.92 | −$50.4M | $44K | −$50.5M | Mar 7 |
| Q3 2023 · Sep 30 | — | — | — | −$69.6M | −$69.8M | — | -16.40 | −$51.3M | $281K | −$51.6M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $120.8M | — | $35.9M | $32.7M | 27.1% | 2.57 | −$50.9M | $0 | −$50.9M | — | — |
| FY2024 · to Dec 31 | $128.9M | — | −$83.4M | −$85.4M | -66.2% | -11.41 | −$68.7M | $246K | −$69M | — | — |
| FY2023 · to Dec 31 | $8.6M | — | −$276M | −$276.1M | -3220.9% | -65.19 | −$193M | $1.2M | −$194.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$280.5M | −$228.3M | — | -2.24 | −$270.4M | $4.2M | −$274.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$340.5M | −$340.1M | — | -3.63 | −$220.5M | $10.6M | −$231.1M | — | — |
| FY2020 · to Dec 31 | — | — | −$309.1M | −$306.6M | — | -4.15 | −$180.8M | $4.5M | −$185.3M | — | — |
Every number comes from Atara Biotherapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.